These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23978358)

  • 1. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
    Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
    Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
    Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.
    Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
    Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
    Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
    Amin HS; Parikh PK; Ghate MD
    Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
    Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
    Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
    Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
    Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
    Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
    Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
    J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
    Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
    Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
    Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
    Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
    Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
    J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.